Literature DB >> 21464094

Physiologic control of the functional status of Foxp3+ regulatory T cells.

Andrew L Mellor1, David H Munn.   

Abstract

Foxp3-lineage CD4 regulatory T cells (Tregs) were named for their ability to maintain self tolerance and suppress T cell immunity. However, resting Tregs from noninflamed tissues exhibit little suppressor activity, and must be stimulated to acquire such function. Conversely, under certain inflammatory conditions, Tregs may undergo rapid reprogramming to acquire helper/effector functions. In this Brief Review, we describe recent progress in elucidating physiologic processes that control the functional status of Foxp3-lineage Tregs. Emerging evidence suggests the surprising possibility that reprogrammed Tregs can be an indispensable source of helper activity in some physiologic settings, such as priming CD8(+) T cell responses. This suggests a novel paradigm in which Foxp3(+) Tregs intrinsically possess bifunctional potential, acting as a preformed pool of first-responder cells at sites of local inflammation that can either provide classical regulatory/suppressor activity, or rapidly reprogram to supply helper/effector activity, contingent on signals that manifest in local physiologic settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464094      PMCID: PMC3808246          DOI: 10.4049/jimmunol.1002937

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Science       Date:  2003-01-16       Impact factor: 47.728

2.  CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset.

Authors:  Markus Kleinewietfeld; Fabiola Puentes; Giovanna Borsellino; Luca Battistini; Olaf Rötzschke; Kirsten Falk
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

Review 3.  The T-cell receptor repertoire of regulatory T cells.

Authors:  Rafal Pacholczyk; Joanna Kern
Journal:  Immunology       Date:  2008-12       Impact factor: 7.397

4.  Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity.

Authors:  Noriko Komatsu; Maria Encarnita Mariotti-Ferrandiz; Ying Wang; Bernard Malissen; Herman Waldmann; Shohei Hori
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

5.  Activation requirements for the induction of CD4+CD25+ T cell suppressor function.

Authors:  Angela M Thornton; Ciriaco A Piccirillo; Ethan M Shevach
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

6.  Foxp3 processing by proprotein convertases and control of regulatory T cell function.

Authors:  Edwin F de Zoeten; Iris Lee; Liqing Wang; Chunxia Chen; Guanghui Ge; Andrew D Wells; Wayne W Hancock; Engin Ozkaynak
Journal:  J Biol Chem       Date:  2008-12-24       Impact factor: 5.157

7.  How does the immune response get started?

Authors:  Melvin Cohn
Journal:  Cell Immunol       Date:  2008-11-20       Impact factor: 4.868

8.  Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node.

Authors:  Eileen T Samy; Lucy A Parker; Colin P Sharp; Kenneth S K Tung
Journal:  J Exp Med       Date:  2005-09-19       Impact factor: 14.307

9.  Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells.

Authors:  Hiroyoshi Nishikawa; Takuma Kato; Isao Tawara; Kanako Saito; Hiroaki Ikeda; Kagemasa Kuribayashi; Paul M Allen; Robert D Schreiber; Shimon Sakaguchi; Lloyd J Old; Hiroshi Shiku
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

10.  Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state.

Authors:  Sylvain Fisson; Guillaume Darrasse-Jèze; Elena Litvinova; Franck Septier; David Klatzmann; Roland Liblau; Benoît L Salomon
Journal:  J Exp Med       Date:  2003-08-25       Impact factor: 14.307

View more
  30 in total

Review 1.  Highlights of 10 years of immunology in Nature Reviews Immunology.

Authors:  Ruslan Medzhitov; Ethan M Shevach; Giorgio Trinchieri; Andrew L Mellor; David H Munn; Siamon Gordon; Peter Libby; Göran K Hansson; Ken Shortman; Chen Dong; Dmitry Gabrilovich; Leona Gabryšová; Ashleigh Howes; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

2.  Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia.

Authors:  Giovanni Sais; Stephen Wyler; Tvrtko Hudolin; Irina Banzola; Chantal Mengus; Lukas Bubendorf; Peter J Wild; Hans H Hirsch; Tullio Sulser; Giulio C Spagnoli; Maurizio Provenzano
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  Association of peripheral NK cell counts with Helios+ IFN-γ- Tregs in patients with good long-term renal allograft function.

Authors:  K Trojan; L Zhu; M Aly; R Weimer; N Bulut; C Morath; G Opelz; V Daniel
Journal:  Clin Exp Immunol       Date:  2017-03-13       Impact factor: 4.330

4.  Physiologic control of IDO competence in splenic dendritic cells.

Authors:  Babak Baban; Phillip R Chandler; Burles A Johnson; Lei Huang; Minghui Li; Marlon L Sharpe; Loise M Francisco; Arlene H Sharpe; Bruce R Blazar; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

5.  IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Authors:  Richard Metz; Courtney Smith; James B DuHadaway; Phillip Chandler; Babak Baban; Lauren M F Merlo; Elizabeth Pigott; Martin P Keough; Sonja Rust; Andrew L Mellor; Laura Mandik-Nayak; Alexander J Muller; George C Prendergast
Journal:  Int Immunol       Date:  2014-01-08       Impact factor: 4.823

Review 6.  Tregs and infections: on the potential value of modifying their function.

Authors:  Sharvan Sehrawat; Barry T Rouse
Journal:  J Leukoc Biol       Date:  2011-09-13       Impact factor: 4.962

7.  Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase.

Authors:  Mee Young Chang; Courtney Smith; James B DuHadaway; Jennifer R Pyle; Janette Boulden; Alejandro Peralta Soler; Alexander J Muller; Lisa D Laury-Kleintop; George C Prendergast
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

Review 8.  STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?

Authors:  Henrique Lemos; Lei Huang; Tracy McGaha; Andrew L Mellor
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 9.  The role of FcεRI expressed in dendritic cells and monocytes.

Authors:  Jeoung-Sook Shin; Alexandra M Greer
Journal:  Cell Mol Life Sci       Date:  2015-02-26       Impact factor: 9.261

10.  Targeted disruption of organic cation transporter 3 (Oct3) ameliorates ischemic brain damage through modulating histamine and regulatory T cells.

Authors:  Pengxiang Zhu; Ryuji Hata; Masahito Ogasawara; Fang Cao; Kenji Kameda; Kohei Yamauchi; Alfred H Schinkel; Kazutaka Maeyama; Masahiro Sakanaka
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-27       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.